BioNTech (NASDAQ:BNTX) Receives "Buy" Rating from HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of BioNTech (NASDAQ:BNTX - Free Report) in a report released on Tuesday, Benzinga reports. They currently have a $113.00 price target on the stock.

Other equities research analysts have also recently issued reports about the company. Evercore ISI began coverage on BioNTech in a research note on Tuesday, May 14th. They set an inline rating and a $100.00 price objective on the stock. TD Cowen cut their target price on BioNTech from $98.00 to $85.00 and set a hold rating on the stock in a research note on Tuesday, August 6th. HSBC raised BioNTech from a hold rating to a buy rating in a research note on Friday, August 2nd. BMO Capital Markets cut their target price on BioNTech from $123.00 to $122.00 and set an outperform rating on the stock in a research note on Tuesday, May 7th. Finally, Hsbc Global Res raised BioNTech from a hold rating to a strong-buy rating in a research note on Friday, August 2nd. One analyst has rated the stock with a sell rating, five have assigned a hold rating, five have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of Moderate Buy and an average price target of $109.09.

BioNTech Trading Down 0.5 %

NASDAQ BNTX traded down $0.40 during trading hours on Tuesday, hitting $87.11. 321,254 shares of the company were exchanged, compared to its average volume of 697,878. The stock has a 50-day moving average price of $83.86 and a 200 day moving average price of $89.44. The company has a quick ratio of 11.16, a current ratio of 11.38 and a debt-to-equity ratio of 0.01. BioNTech has a 52 week low of $76.53 and a 52 week high of $125.83. The stock has a market cap of $20.71 billion, a PE ratio of 175.02 and a beta of 0.23.

BioNTech (NASDAQ:BNTX - Get Free Report) last issued its quarterly earnings data on Monday, August 5th. The company reported ($3.36) earnings per share for the quarter, missing the consensus estimate of ($2.02) by ($1.34). BioNTech had a return on equity of 0.55% and a net margin of 4.01%. The company had revenue of $128.70 million for the quarter, compared to the consensus estimate of $134.98 million. During the same period in the previous year, the firm earned ($0.86) earnings per share. The company's revenue was down 23.3% compared to the same quarter last year. Analysts forecast that BioNTech will post -2.04 earnings per share for the current fiscal year.

Institutional Trading of BioNTech

A number of hedge funds have recently bought and sold shares of BNTX. GAMMA Investing LLC lifted its holdings in BioNTech by 121.0% during the first quarter. GAMMA Investing LLC now owns 274 shares of the company's stock worth $25,000 after buying an additional 150 shares during the period. CWM LLC lifted its holdings in BioNTech by 657.6% during the fourth quarter. CWM LLC now owns 250 shares of the company's stock worth $26,000 after buying an additional 217 shares during the period. Frazier Financial Advisors LLC purchased a new stake in BioNTech during the fourth quarter worth $30,000. First Horizon Advisors Inc. purchased a new stake in BioNTech during the fourth quarter worth $38,000. Finally, Covestor Ltd lifted its holdings in BioNTech by 47.2% during the first quarter. Covestor Ltd now owns 415 shares of the company's stock worth $38,000 after buying an additional 133 shares during the period. Hedge funds and other institutional investors own 15.52% of the company's stock.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.